Compare Peloton Interactive Inc (PTON) vs 10X Genomics Inc (TXG) Price & Performance

Peloton (PTON) trades at $4.85, down 0.41% on the day, amid a bearish technical signal and mixed earnings history. The company reported its first full-year net profit in 2026 with a 2.58% net income margin, yet revenue has declined from $3.6B in 2022 to $2.4B in 2026. Positive cash flow trends and a new product launch, including a foldable treadmill, aim to revive growth, but negative shareholder equity and high debt levels persist as concerns.

The outlook hinges on execution of the turnaround strategy; upside exists if new products boost subscriptions, but risks include persistent subscriber declines and high leverage. Analyst consensus is a Buy with a $8.00 price target, suggesting significant potential appreciation from current levels if operational improvements continue.

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.